公开(公告)号：US20190004045A1

公开(公告)日：2019-01-03

申请号：US16123385

申请日：2018-09-06

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. COHEN ,  Eytan DOMANY ,  Francisco Javier QUINTANA ,  Guy HED ,  Gad GETZ

IPC: G01N33/564 ,  G01N33/68 ,  G06F19/18

Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.

公开(公告)号：US20160033529A1

公开(公告)日：2016-02-04

申请号：US14883685

申请日：2015-10-15

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF

Inventor： Eran OVADIA ,  Irun R. COHEN ,  Johannes HERKEL ,  Raanan MARGALIT ,  Meirav PEVSNER-FISCHER

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  A61K31/343 ,  A61K38/08 ,  A61K38/1808 ,  A61K38/1825 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/185 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/30 ,  A61K45/06 ,  C07K7/06 ,  G01N33/54306 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract translation: 本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。 本发明还提供了评估对本发明的肽的治疗反应性的方法。 此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。

公开(公告)号：US20140323355A1

公开(公告)日：2014-10-30

申请号：US14265914

申请日：2014-04-30

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  MOR - RESEARCH APPLICATIONS LTD.

Inventor： Irun R. COHEN ,  Meirav PEVSNER-FISCHER ,  David MARGEL ,  Jack BANIEL ,  Ofer YOSSEPOWITCH

IPC: G01N33/574

CPC classification number: G01N33/57407 ,  G01N33/57434 ,  G01N33/57488 ,  G01N2333/5428 ,  G01N2333/5437 ,  G01N2333/545

Abstract: The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.

Abstract translation: 本发明涉及癌症诊断领域，特别涉及膀胱癌（BC）和前列腺癌（CaP）的诊断。 更具体地，本发明提供了以高灵敏度和特异性为特征的简单的非侵入性尿检，其中使用热休克蛋白和抗炎细胞因子的尿酸水平作为生物标志物。